Evidence map›Paper›PMID 35362685›Full record

ArticleSe pu = Chinese journal of chromatography2022

[Application of magnetic immunofluorescence assay based on microfluidic technology to detection of Epstein-Barr virus].

Junhao Li, Guanhua Han, Xiaotao Lin, Liqiang Wu, Chungen Qian, Junfa Xu

Open access · greenAbstract read
In one paragraph

Article in Se pu = Chinese journal of chromatography, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Junhao LiDepartment of Clinical Immunology, Institute of Laboratory Medicine, Medical Technology College, Guangdong Medical University, Dongguan 523808, China.
Guanhua HanDepartment of Clinical Immunology, Institute of Laboratory Medicine, Medical Technology College, Guangdong Medical University, Dongguan 523808, China.
Xiaotao LinShenzhen YHLO Biotechnology Company Limited, Shenzhen 518100, China.
Liqiang WuShenzhen YHLO Biotechnology Company Limited, Shenzhen 518100, China.
Chungen QianShenzhen YHLO Biotechnology Company Limited, Shenzhen 518100, China.
Junfa XuDepartment of Clinical Immunology, Institute of Laboratory Medicine, Medical Technology College, Guangdong Medical University, Dongguan 523808, China.
Guangdong Medical College · CNShenzhen Bioeasy Biotechnology (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early diagnosis of Epstein-Barr virus (EBV) can reduce the risk of major illnesses. Disadvantages of EBV antibody detection methods that are commonly used clinically include lengthy assay time, need for a lot of reagent, and low efficiency. Compared with traditional detection methods, microfluidics technology offers high throughput, low reagent consumption, less bio-contamination, and a higher degree of automation. Advantages of magnetic immunofluorescence technology include high detection efficiency and a strong signal. The combined advantages of the two methods can compensate for the shortcomings of traditional methods. In the present study, polymethyl methacrylate (PMMA) as the raw material was subjected to laser cutting and vacuum hot pressing to quickly obtain chips. Magnetic beads labeled with antigen and fluorescent microspheres labeled with anti-human antibody were then rapidly lyophilized into microspheres by freeze-drying and embedded into the chips. After incubation and cleaning, the last step was detection. Image J software was used to analyze the mean fluorescence intensity and obtain negative or positive test results. To determine the precision of the chip, high- and low-value samples of each item were retested 10 times. The mean values were calculated to obtain the relative standard deviation (RSD) for several common pathogens. Furthermore, the coincidence rate of clinical samples was tested using a chemiluminescence immunoassay (CLIA) to determine the potential clinical application value. The RSD of the precision test for each item was <10%, indicating good precision. The precision of the accelerated stability test was not verified. Specificity test results revealed no cross-reaction with some common pathogen antibodies, indicating good specificity. It remains to be verified whether the antibodies detected by this method cross-react with other herpes simplex viruses, such as types 1 and 2, Kaposi's sarcoma-associated virus, and human herpes virus type 6 and 7. Of the 121 clinical samples tested, statistical analysis of the data indicated good agreement with the chemiluminescence immunoassay in clinical trials. EB viral capsid antigen (EB VCA) IgG positive coincidence rate was 95.77% (68/71), the negative coincidence rate was 86% (43/50) (Kappa=0.828,

Indexed as

Epstein-Barr Virus InfectionsHerpesvirus 4, HumanFluorescent Antibody TechniqueHumansMagnetic PhenomenaMicrofluidicsTechnologyEpstein-Barr virus (EBV)magnetic immunofluorescencemicrofluidicrapid detection

Identifiers

PMID35362685
PMCPMC9404092
OpenAlexW4226088042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.